Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type

Pharm Res. 2019 Mar 13;36(5):66. doi: 10.1007/s11095-019-2602-y.

Abstract

Purpose: Hypovascularization of cervical tumors, coupled with intrinsic and acquired drug resistance, has contributed to marginal therapeutic outcomes by hindering chemotherapeutic transport and efficacy. Recently, the heterogeneous penetration and distribution of cell penetrating peptide (CPP, here MPG) and polyethylene glycol (PEG) modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were evaluated as a function of tumor type and morphology in cervical cancer spheroids modeling hypovascularized tumor nodules. Building upon this work, this study investigates the efficacy imparted by surface-modified Doxorubicin-loaded NPs transported into hypovascularized tissue.

Methods: NP efficacy was measured in HeLa, CaSki, and SiHa cells. NP internalization and association, and associated cell viability, were determined in monolayer and spheroid models.

Results: MPG and PEG-NP co-treatment was most efficacious in HeLa cells, while PEG NPs were most efficacious in CaSki cells. NP surface-modifications were unable to improve efficacy, relative to unmodified NPs, in SiHa cells.

Conclusions: The results highlight the dependence of efficacy on tumor type and the associated microenvironment. The results further relate previous NP transport studies to efficacy, as a function of surface-modification and cell type. Longer-term, this information may help guide the design of NP-mediated strategies to maximize efficacy based on patient-specific cervical tumor origin and characteristics.

Keywords: 3D cell culture; cell penetrating peptide (CPP); cervical cancer; nanoparticles; nanotherapy.

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Antibiotics, Antineoplastic / pharmacology
  • Cell Line, Tumor
  • Cell-Penetrating Peptides / chemistry
  • Cell-Penetrating Peptides / metabolism*
  • Cervix Uteri / blood supply
  • Cervix Uteri / drug effects
  • Cervix Uteri / metabolism
  • Cervix Uteri / pathology
  • Doxorubicin / administration & dosage*
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism*
  • Female
  • HeLa Cells
  • Humans
  • Nanoparticles / chemistry
  • Nanoparticles / metabolism*
  • Polyethylene Glycols / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer / metabolism
  • Uterine Cervical Neoplasms / blood supply
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / pathology

Substances

  • Antibiotics, Antineoplastic
  • Cell-Penetrating Peptides
  • Drug Carriers
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyethylene Glycols
  • Doxorubicin